Mast Therapeutics (MSTX) : During the past 4 weeks, traders have been relatively bearish on Mast Therapeutics (MSTX), hence the stock is down -23.2% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -18.58% relative to the S&P 500. The 4-week change in the price of the stock is -20.62% and the stock has fallen -18.63% in the past 1 week.
The stock has recorded a 20-day Moving Average of 17.77% and the 50-Day Moving Average is 12.83%. Mast Therapeutics, Inc. is up 19.07% in the last 3-month period. Year-to-Date the stock performance stands at -14.95%.
Mast Therapeutics (NYSEMKT:MSTX): On Fridays trading session , Opening price of the stock was $0.36 with an intraday high of $0.3698. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $0.34. However, the stock managed to close at $0.3572, a loss of 1.62% for the day. On the previous day, the stock had closed at $0.3631. The total traded volume of the day was 2,858,388 shares.
Mast Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops therapies for serious or life-threatening diseases with unmet needs. The Company leverages its Molecular Adhesion and Sealant Technology (MAST) platform, to develop MST-188 (vepoloxamer) Injection, the Companys lead product candidate. Vepoloxamer is being tested in a Phase III clinical study called EPIC for the treatment of vaso-occlusive crisis in patients with sickle cell disease. The Company also develops AIR001, a sodium nitrite solution for intermittent inhalation through nebulizer. AIR001 is being tested in multiple institution-sponsored Phase IIa clinical studies that provide the Company with data on AIR001s potential to treat patients with preserved ejection fraction (HFpEF).